Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT04481204
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Therapy in Biliary Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Jordan Kharofa
- Registration Number
- NCT04480190
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 335
- Registration Number
- NCT04456699
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias ( Site 1153), Oviedo, Asturias, Spain
🇺🇸Providence Portland Medical Center ( Site 1400), Portland, Oregon, United States
🇺🇸Oregon Health & Science University ( Site 1411), Portland, Oregon, United States
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Krankenhaus Nordwest
- Target Recruit Count
- 200
- Registration Number
- NCT04447352
- Locations
- 🇩🇪
Uniklinik RWTH Aachen, AöR, Medizinische Klinik III, Studienzentrum Viszeralmedizin, Aachen, Germany
🇩🇪Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany, Frankfurt, Germany
🇩🇪Universitätsklinikum, Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden, Germany
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 326
- Registration Number
- NCT04442984
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Dorte Nielsen
- Registration Number
- NCT04430985
- Locations
- 🇩🇰
Herlev University Hospital, Department of Oncology, Herlev, Denmark
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04430738
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇯🇵National Cancer Center Hospital, Chuo-ku, Other, Japan
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 374
- Registration Number
- NCT04420884
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 538
- Registration Number
- NCT04393584
- Locations
- 🇷🇺
Aleksei Kalinin, Moscow, Russian Federation
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04390399
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag memorial Presbyterian Hospital, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.